[Laboratory and clinical studies of flomoxef].
Laboratory and clinical studies were performed on a new oxacephem antibiotic, flomoxef (FMOX, 6315-S). In vitro antibacterial activity of FMOX was evaluated in comparison to latamoxef (LMOX), cefmetazole (CMZ), cefazolin (CEZ) using clinically isolated strains of Gram-negative and Gram-positive bacteria. Antibacterial activities of FMOX were stronger than LMOX, CMZ, CEZ against Escherichia coli, Klebsiella but only slightly effective against Staphylococcus aureus. This antibiotic drug was administered to 5 patients consisting of 2 cases with pneumonia, one each with pyelonephritis, chronic bronchitis and urinary tract infection. The drug was given in 1 g drip infusion twice a day for 8 to 13 days. Clinical efficacies of FMOX were excellent in 1 case, good in 2, fair in 1, and unevaluable in 1. As for bacteriological effect of FMOX, organisms were eradicated in 3 cases. No side effect was noted and there was no abnormal change in laboratory findings.
Nozue
N
N
Second Department of Internal Medicine, School of Medicine, Teikyo University.
Ueda
Y
Y
Haga
T
T
Muraoka
A
A
Ono
Y
Y
Nishiya
H
H
Miyashita
H
H
D000328:Adult; D001419:Bacteria / Q000187:drug effects* / Q000254:growth & development; D001424:Bacterial Infections / Q000188:drug therapy*; D002437:Cefazolin / Q000494:pharmacology; D015311:Cefmetazole; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002513:Cephamycins / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007709:Klebsiella / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009070:Moxalactam / Q000494:pharmacology
D002511:Cephalosporins; D002513:Cephamycins; D015311:Cefmetazole; D002437:Cefazolin; C045693:flomoxef; D009070:Moxalactam